Pipeline

BBOT shakes up leadership as RAS competitors get more visibility

BioSpace

Chief Scientific Officer Pedro Beltran will succeed Eli Wallace as CEO of BridgeBio Oncology Therapeutics, as the board eyes a busy period of clinical advancement in the RAS oncology space.

Pipeline Oncology Read full story

pharminent April 23, 2026 (Last updated: April 23, 2026)

BioSpace

Chief Scientific Officer Pedro Beltran will succeed Eli Wallace as CEO of BridgeBio Oncology Therapeutics, as the board eyes a busy period of clinical advancement in the RAS oncology space.

Pipeline Oncology Read full story

Related Stories

In Alzheimer’s, Bristol Myers sees big promise beyond amyloid

Remepy’s hybrid Parkinson’s therapy poised for phase 3

Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update

You May Have Missed

Eli Lilly issues data sharing ultimatum to 340B hospitals

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma

ASCO26: In vivo oncology approaches continue to show promise